KI Holdings Ltd. acquired 10,000,000 Hepion Pharmaceuticals common shares, giving the reporting persons a 10.2% stake, and received a Warrant for up to 10,000,000 additional shares at $0.06 each. The warrant is immediately exercisable, while the investors may acquire more securities, sell holdings or maintain their position.

Key Highlights

  • KI Holdings Ltd. received a warrant covering up to 10,000,000 additional Hepion Pharmaceuticals common shares.
  • Donald Kivowitz may be deemed to beneficially own the securities through his relationship with KI Holdings Ltd.
  • KI Holdings and Donald Kivowitz report beneficial ownership of 10.2% of Hepion Pharmaceuticals’ common stock.

Hepion Pharmaceuticals, Inc. now has a reporting person holding 10.2% of its common stock after KI Holdings Ltd. acquired 10,000,000 shares. The purchase also included a warrant for up to 10,000,000 additional common shares, with an aggregate purchase price of $500,000.

$500,000 Private Placement Adds Warrant Rights

KI Holdings completed the Acquisition on Aug. 3, 2026, under a Securities Purchase Agreement dated July 31, 2026, in a private placement with Hepion Pharmaceuticals and other purchasers. The purchase price came from KI Holdings’ working capital. Donald Kivowitz did not directly buy the securities. He may be deemed to beneficially own them through his relationship with KI Holdings, which is an Investment Holding Company formed in Texas. Kivowitz is identified as a United States citizen, Business executive and investor.

Investors May Change or Maintain Their Position

The reporting persons said they acquired the securities for investment purposes and intend to keep reviewing the investment on a continuing basis. The investors may also dispose of some or all of their securities or maintain their current position. Other than the transaction described, the reporting persons stated they have no present plans or proposals relating to the specified corporate actions covered by their disclosure.